Effect of Psoralen on the Intestinal Barrier and Alveolar Bone Loss in Rats With Chronic Periodontitis

Hua Liu,1 Yingjie Xu,2 Qi Cui,2 Ning Liu,2 Fuhang Chu,2 Beibei Cong,2 and Yingtao Wu2,3

(Received January 26, 2021; Revised March 29, 2021; accepted April 1, 2021)

Abstract—To study the effects of psoralen on the intestinal barrier and alveolar bone loss (ABL) in rats with chronic periodontitis. Fifty-two 8-week-old specific pathogen-free (SPF) male Sprague-Dawley (SD) rats were randomly divided into the following four groups: Control group (Control), psoralen group of healthy rats (Pso), periodontitis model group (Model), and psoralen group of periodontitis rats (Peri+Pso). The alveolar bone resorption of maxillary molars was observed via haematoxylin-eosin staining and micro-computed tomography. The expression level of receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin (OPG) in periodontal tissues was evaluated by immunofluorescence staining. The expression level of receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin (OPG) in periodontal tissues was evaluated by immunofluorescence staining. The changes in serum tumour necrosis factor (TNF)-α, interleukin (IL)-10, IL-6, intestinal mucosal occludin, and claudin-5 were detected using enzyme-linked immunosorbent assay (ELISA). The level of intestinal mucosal NOD2 was detected using immunohistochemical methods. DNA was extracted from the intestinal contents and the 16s rRNA gene was sequenced using an Illumina MiSeq platform. The expression of NOD2 protein in the intestinal tract of periodontitis rats decreased after intragastric psoralen administration. Psoralen increased the intestinal microbiota diversity of rats. The level of serum pro-inflammatory factor TNF-α decreased and the level of anti-inflammatory factor IL-10 increased. ABL was observed to be significantly decreased in rats treated with psoralen. Psoralen decreased the RANKL/OPG ratio of periodontitis rats. Psoralen may affect the intestinal immune barrier and ecological barrier, mediate immune response, promote the secretion of anti-inflammatory factor IL-10, and reduce the secretion of the pro-inflammatory factor TNF-α, thus reducing ABL in experimental periodontitis in rats.

KEY WORDS: psoralen; periodontitis; intestinal barrier; alveolar bone loss.

INTRODUCTION

Chronic periodontitis is a chronic inflammatory disease characterised by periodontal tissue destruction, and this tissue destruction is characterised by gingival inflammation, periodontal pocket formation, and alveolar bone resorption [1, 2]. Therefore, the treatment of periodontitis can control the inflammatory response, prevent further
tissue damage, and promote periodontal tissue regeneration. Periodontitis is primarily treated via mechanical means such as subgingival scaling. In addition, periodontal surgery and drug therapy are also important periodontitis treatment methods. Drug treatment mainly depends on antibiotics, but it is associated with certain challenges, such as drug resistance and oral flora imbalance [3]. Therefore, it is necessary to study new preparations that have antibacterial and anti-inflammatory effects and can reduce alveolar bone resorption.

In chronic periodontitis, increased permeability of the gingival epithelium causes microorganisms, endotoxins, and inflammatory factors to infiltrate the bloodstream throughout the body, causing systemic responses, including intestinal responses, to trigger an immune response from the host, which in turn exacerbates the destruction of periodontal support tissue [4, 5]. Some studies have shown that the imbalance of oral microflora affects individual microflora and is related to various systemic diseases including gastrointestinal and nervous system diseases [6]. In summary, chronic periodontitis changes the composition and structure of microbial communities in the oral and intestinal tract [7]. In addition, *Porphyromonas gingivalis* is a Gram-positive anaerobe closely related to the progression of chronic periodontitis [8]. *Porphyromonas gingivalis* can cause changes in the composition of intestinal microflora, the regulation of intestinal immune system, and the impairment of intestinal barrier function, resulting in an increase in systemic inflammation and related pathology [9–11].

However, the intestinal tract is not only a digestive organ but also an immune organ. There is an interactive relationship between the intestinal mucosal immune system and the intestinal flora. The immune system can recognise microorganisms and secrete cytokines and antibodies to maintain the homeostasis of the intestinal environment through innate and adaptive immunity. The weakening of the intestinal epithelial barrier leads to the invasion of intestinal pathogenic bacteria and the secretion of harmful metabolites into the host. When various internal and external factors destroy the balance between the intestinal microecosystem and the host, the intestinal microflora can invade the host as an antigen, triggering a series of immune responses, leading to changes in bone mass and structure. A close relationship has been reported between the bones and the immune system, and some scholars have put forward the concept of ‘bone immunity’ [12]. As a part of the skeletal system, alveolar bone plays an active role in metabolism and remodelling of the skeletal system. Different from other bones in the body, the bone remodelling process of alveolar bone is affected by both the local oral environment and systemic factors. Some studies have found that *Lactobacillus* can affect the metabolism of the alveolar bone by influencing the absorption of minerals of the host. In addition, it can also affect alveolar bone mass by inhibiting the proliferation and differentiation of osteoclasts [13].

*Fructus psoraleae* is a type of traditional Chinese medicine, which has anti-inflammatory [14], anti-tumour, antibacterial, antifungal, immunomodulatory, oestrogenic, and osteogenic activities [15], and is widely used in the treatment of osteoporosis. Psoralen is an effective component isolated from psoralea. At present, the osteogenic effect of psoralen has been widely studied. *In vitro* experiments have shown that psoralen promotes osteogenic differentiation by increasing alkaline phosphatase (ALP) activity in human periodontal ligament cells (HPDLCs) and upregulating osteogenic genes and proteins (RUNX2, DLX5, and OPG) [16]. It can also inhibit osteoporosis in ovariectomised rats by stimulating bone marrow mesenchymal stem cells to differentiate into osteoblasts [17]. For most traditional Chinese medicine, oral administration is the most convenient route, as its effective components are absorbed, distributed, and metabolised in as well as excreted from the human body. The transformation of intestinal bacteria is the key link that leads to the production of more active compounds in the digestive tract. At present, some plasma pharmacokinetic studies of psoralen have shown that it has rapid oral absorption in the enterohepatic circulation [18]. Based on these findings, we hypothesised that psoralen could improve alveolar bone resorption in periodontitis rats by regulating the intestinal barrier. In this study, a rat model of periodontitis was established and psoralen was administered intragastrically to observe the changes in the intestinal barrier, the levels of serum inflammatory factors in rats with periodontitis, and their effects on alveolar bone loss (ABL) in periodontitis rats.

**MATERIALS AND METHODS**

**Periodontitis Rat Model**

All animal-related experiments were performed using the protocols approved by our institute (The Ethics Committee of Qingdao Stomatological Hospital Affiliated to Qingdao University, 2019KQYX018). Fifty-two 8-week-old male Sprague-Dawley (SD) rats and weighing 350 ± 20 g were purchased from Shandong Experimental Animal Center. They were caged in specific pathogen-free (SPF)
Effect of Psoralen

Conditioned, fed with a normal diet, and subjected to constant temperature and humidity for 12 h each of alternating light/darkness. One week later, adaptive feeding was included in the experiment. The 52 rats were randomly divided into four groups ($n = 13$ each group): (1) Control group (Control); (2) healthy rats treated with psoralen group (Pso); (3) periodontitis model group (Model), and (4) periodontitis rats treated with psoralen group (Peri+Pso). The periodontitis modelling method was conducted as follows: mice were anaesthetised with 10% chloral hydrate via intraperitoneal injection at a dosage of 0.3 mL/100 g body weight, fixed, and disinfected, and the gingival tissue of the bilateral maxillary second molars (M2) was separated using a sharp probe. A standard ligating wire (0.25 mm) was passed through the proximal and distal adjacent spaces of the bilateral maxillary M2, ligated around the dental neck, placed in the gingival sulcus as far as possible, and knotted in the mesiobuccal side of M2. The ligation wire was checked daily for shedding and was re-ligated when the wire detached. Periodontal ligation was maintained for 4 weeks to keep periodontal tissue inflammation in a stable state to establish the model of chronic periodontitis [19, 20]. Four weeks after ligation, the periodontal condition of the rats was examined. The following changes were checked: whether the second molar gingiva was red and swollen, bled upon probing, had a deep periodontal pocket, had alveolar bone resorption, and had increased tooth mobility. Two rats were randomly selected and sacrificed, and the bilateral maxilla and a 2 cm long ileum tissue were immediately removed and fixed in 4% paraformaldehyde for 24 h. The fresh ileum content (approximately 3–5 g) and another 2 cm ileum tissue segment were respectively placed in a 1.5 mL Eppendorf tube aseptically, temporarily stored in an icebox, and then stored at $-80^\circ$C until use.

HE Staining and Immunofluorescence Staining of Alveolar Bone

The 4% paraformaldehyde-fixed alveolar bone was then decalcified using a 10% EDTA decalcification solution for 4 weeks. The samples were routinely dehydrated, embedded, and sliced along the proximal and distal direction at a distance of 5 μm. The samples were HE-stained to observe periodontal tissue inflammation and ABL. The sections were placed in citrate buffer and repaired by 30 min at 37°C in microwave oven. Inactivate endogenous peroxidase by dropping 3% hydrogen peroxide solution. The inactivated sections were incubated with rabbit anti-mouse OPG antibody (Servicebio, GB11151, 1:200) and rabbit anti-mouse RANKL antibody (Servicebio, GB11253, 1:100) at 4°C overnight and washed with TBS for 3 times. The sections of each group were treated with fluorescence coupled second antibody and incubated at 37°C for 1 h. The fluorescence intensity detected by fluorescence microscope showed that the positive expression of OPG was red and the positive expression of RANKL was green. Immunofluorescence staining was used to observe the expression level of RANKL and OPG in periodontal tissues.

Micro-CT Analysis of Alveolar Bone

The maxilla of rats were scanned using a μCT100 micro-computed tomography (SCANCO Medical AG), with a voxel resolution of 15 μm. Mimics-Research 20.0 software was used for three-dimensional reconstruction, and the amount of ABL was evaluated by measuring the average distance from the mesial, central, and distal alveolar crest to the enamel bone boundary of the buccal and palatal side of the second molar [20]. CT analyser 1.18 software (Bruker) was used to analyse the histomorphometry of trabecular bone in the region of interest (ROI), including bone volume per tissue volume and trabecular volume separation. The ROI was defined as the 0.4 mm³ rectangle of the alveolar bone of the maxillary second molar.
Analysis of Occludin and Claudin-5 Expression in the Ileal Mucosa

Fresh ileal tissue (~2 cm) was obtained from each sample, homogenised using a homogeniser, and centrifuged for approximately 20 min (1610×g). The supernatant was collected carefully, strictly following the instructions of the rat occludin ELISA kit (ELISA, enzyme-linked immunosorbent assay) and rat claudin-5 ELISA kit manufacturers, respectively. A standard curve was established, and the levels of occludin and claudin-5 in the ileal mucosa of each sample were determined.

NOD2 Expression Analysis in the Ileal Mucosa

The expression of NOD2 in the intestinal mucosa was detected using immunohistochemical methods. The tissue sections were dewaxed and the antigens were retrieved. The sections were placed in a 3% hydrogen peroxide solution and incubated at 25 °C for 10 min to block the endogenous peroxidase. Normal goat serum blocking solution was then added and incubated at room temperature for 15 min. Next, 50 μL goat anti-mouse NOD2 polyclonal antibody (Santa Cruz Biotechnology) was added (1:150 dilution) and the samples were incubated overnight at 4 °C, rinsed with phosphate-buffered saline (PBS) thrice, and finally, the biotin-labelled secondary antibody was added. After incubation at room temperature for 20 min, the degree of colouration was controlled by viewing under the microscope, and the colour reaction was terminated with distilled water. The samples were then re-stained with haematoxylin for 30–60 s, the sheets were dehydrated until transparent, and a neutral gum seal was added. After scanning each section, six visual fields were randomly selected using Case Viewer 2.4. The positive cells were semi-quantitatively counted using the Image-Pro Plus 6.0 software. The data were expressed as integrated optical density (IOD).

Sequencing of 16S rRNA and Data Analysis of Intestinal Flora in the Ileum

After genomic DNA was extracted from the ileal samples, its concentration and purity were detected using 1% agarose gel electrophoresis. The V3 and V4 regions of the bacterial 16s rRNA were amplified using PCR. The upstream and downstream primers used were as follows: 338F: 5′-ACTCCTACGGGAGGCAGCAG-3′ and 806R: 5′-GGACTACHVGGGTWTCTAAT-3′. The amplification program was set as follows: 94 °C for 5 min, 94 °C for 30 s, 55 °C for 30 s, 28 cycles of 72 °C for 60 s, and 72 °C for 7 min. A MiSeq library was constructed using the PCR products, and high quality data was analysed using the bioinformatics suite provided by the Illumina MiSeq platform.

Analysis of Serum Inflammatory Factors

The collected blood was centrifuged at 3000 rpm for 15 min to separate the serum, which was stored at −20 °C until use. A rat IL-6 (IL, interleukin) ELISA kit, rat IL-10 ELISA kit, and rat TNF-α (TNF, tumour necrosis factor) ELISA kit were all purchased from Jiangsu Enzymatic Immunization Company. The levels of IL-6, IL-10, and TNF-α in serum were measured strictly according to the manufacturer’s instructions.

Statistical Analysis

Ileal intestinal flora was analysed using R to calculate the alpha diversity and to perform a species composition analysis. Linear discriminant analysis (LDA), effect size (LEfSe) analysis, and LDA were used to reduce and evaluate the influence of species with significant differences in data (LDA score), and the threshold was set to 3 to find species that had significantly different abundances between the groups. Other data were analysed using the GraphPad Prism 8 software. The difference between the groups was analysed using single factor analysis of variance. Comparisons between the two groups were conducted using a t-test with two independent samples. When P < 0.05, the difference was considered to be statistically significant.

RESULTS

Verification of Periodontitis Modelling in Rats

HE staining showed that the gingival epithelium of rats in the Control group had no pathological changes and the surface of their alveolar bone was smooth. Compared with the Control group, the gingival epithelium of the second molar of the rats in the Model group were found to be thickened, inflammatory cells infiltrated, and the binding epithelium moved away from the enamel bone boundary to the root, thereby resulting in the formation of erosive resorption lacunae on the surface of alveolar bone, and osteoclasts could be observed in the lacuna area (Fig. 1a–d). The three-dimensional reconstruction of the maxillary molars and the alveolar bones of rats after micro-CT scanning showed that the distance from the buccal and palatal alveolar ridge to the enamel bone boundary of the
Effect of Psoralen second maxillary molars of rats in the Model and Peri+Pso groups was larger than that of the Control group (Fig. 1e–h). CEJ-ABC value analysis showed that CEJ-ABC distance in the Model group was significantly larger than that in the Control group ($P < 0.001$) (Fig. 1i).

Effect of Psoralen on Ileal Mechanical Barrier

The protein expression levels of claudin-5 and occludin in the ileal mucosa of rats in each group were detected using ELISA. No considerable differences were found among the four groups (Fig. 2a–b).
Effect of Psoralen on Ileal Immune Barrier

Immunohistochemical sections of rat ileal mucosa showed that NOD2 protein was mainly expressed in the epithelial cells and monocytes. Light yellow granules could be observed in the cytoplasm of a small number of cells in the intestinal mucosa of the Control and Pso groups, and a large amount of dark brown or brown granules could be observed in the cytoplasm of epithelial cells and monocytes in the Model and Peri+Pso groups (Fig. 2d). The NOD2-positive cells were semi-quantitatively counted using the Image-Pro Plus 6.0 software. The data were expressed as IOD. No significant difference was found in the expression of NOD2 protein between the Control and Pso groups. The expression of NOD2 protein in the Model was significantly higher than that in the Control group (P < 0.01). NOD2 expression in the Peri+Pso group was higher than that in the Control group (P < 0.05), but significantly lower than that in the Model group (P < 0.05) (Fig. 2c).

Effect of Psoralen on Ileal Ecological Barrier

The alpha diversity of the intestinal flora in rats of each group was analysed. It was found that the Chao1 index of the Pso and Peri+Pso groups was higher than that of the Control, and the Chao1 index of the Pso group was significantly higher than that of the Control (P < 0.01) (Fig. 3a). The Shannon index of the Pso and Peri+Pso groups was higher than that of the Control, and the Shannon index of the Peri+Pso group was significantly higher than that of the Model group (P < 0.01) (Fig. 3b). Compared with the Control and Model groups, psoralen increased the abundance and diversity of intestinal flora in rats to some extent.

By calculating the Firmicutes/Bacteroidetes (F/B) ratios, we found that the F/B ratio in the Model and Pso groups was lower than that in the Control group (P < 0.001), and that in Peri+Pso group was lower than that in the Model group (P < 0.05) (Fig. 3c). Intestinal flora were compared among groups by further LEfSe analysis, and it was found that there were species with significant
Effect of Psoralen

difference in abundance between each group and the other three groups. The relative contents of o_Clostridiales, c_Clostridia, p_Actinobacteria, and o_Bacillales in the Pso group increased, and that of f_Lactobacillaceae, g_Lactobacillus, o_Lactobacillales, and c_Bacilli in the Model group increased. Furthermore, the relative contents of f_Erysipelotrichaceae, g_Allobaculum, f_Clostridiaceae_1, g_Clostridium_sensu_stricto_1, o_Enterobacteriales, f_Enterobacteriaceae, g_Escherichia_Shigella, s_Escherichia_coli, and p_Bacteroidetes in the Peri+Pso group increased (Fig. 4).

Effect of Psoralen on Alveolar Bone

The distance between the ABC (alveolar bone crest) and CEJ (cemento-enamel junction) in the normal rats was less than 0.25 mm. No significant difference was found in the amount of ABL between the Model and Pso groups, but the amount of ABL in the Model group was significantly higher than that in the Control (\(P < 0.001\)). The amount of ABL in the Peri+Pso group was significantly lower than that in the Control (\(P < 0.05\)), while that in the Peri+Pso group was lower than the Model group (\(P < 0.05\)) (Fig. 5a). Except that, BV/TV of Model group was significantly lower than that of Control group (\(P < 0.01\)) and Peri+Pso group (\(P < 0.05\)) (Fig. 5c), while Tb.Sp was significantly higher than that of Control group (\(P < 0.01\)) and Peri+Pso group (\(P < 0.05\)) (Fig. 5d).

Immunofluorescence staining showed that the expression of OPG increased and the expression of RANKL decreased after administration of psoralen (\(P < 0.01\)) (Fig. 5b).

Effect of Psoralen on Serum Inflammatory Factors

No significant difference was found in the serum pro-inflammatory factor IL-6 between the groups (Fig. 6a). The expression level of TNF-\(\alpha\) in the Model group was significantly higher than that in the Control (\(P < 0.01\)), while that in the Peri+Pso group was lower than the Model group (\(P < 0.05\)) (Fig. 6b). The expression level of the anti-inflammatory factor IL-10 in the serum of rats in the Peri+Pso group was higher than that in Control (\(P < 0.05\)), and significantly higher than the Model group (\(P < 0.01\)) (Fig. 6c).

DISCUSSION

Psoralen, the main active component of psoralea, has many effects, such as cartilage protection and anti-tumour, immune regulation, and anti-vitiligo activities [21]. Recent studies have also found that psoralen can stimulate osteoblast differentiation by activating BMP (bone morphogenetic protein) signals [22]. Psoralen can inhibit bone resorption of osteoclasts in vitro [23]. Additionally, psoralen can treat arthritis by regulating the balance of Th1/Th2 cells and inhibiting the expression of TNF-\(\alpha\), IL-6, and IL-1\(\beta\) [16]. Furthermore, it can also increase the bone mass of ovariectomised rats with osteoporosis by stimulating bone marrow mesenchymal stem cells to differentiate into osteoblasts [17, 21].

Chronic periodontitis is a chronic infectious disease, characterised by gingival inflammation, periodontal pocket
formation, and alveolar bone resorption. Porphyromonas gingivalis is the main dominant bacteria in periodontitis, especially in chronic periodontitis. Recently, it has been found that oral administration of Pseudomonas gingivalis caused changes in the composition of intestinal flora, regulated the intestinal immune system, and impaired intestinal barrier function, thereby resulting in systemic inflammation and related pathological changes [9–11]. Among them, the intestinal barrier, as an important factor affecting systemic inflammation, is composed of a mechanical barrier that composed of epithelium and tight junction proteins, an immune barrier composed of immune cells and immune proteins in the intestinal mucosa, and an ecological barrier composed of normal intestinal flora. The three are closely related in function, and together provide intestinal immunity. The function of the intestinal mechanical barrier mainly depends on the transcellular pathway and the paracellular pathway. The basic structure of the paracellular pathway is the tight junction (TJ) composed of the proteins claudin, occludin, and ZO. The occludin and claudin family of proteins together form the transport pathway, which controls epithelial barrier permeability. Epithelial permeability increases when these proteins are overexpressed [24], causing pathogenic bacteria and related metabolites to invade the body. In this study, no significant difference was found in the protein expression of occludin and claudin-5 among the groups, indicating that psoralen had no significant effect on these proteins in the intestinal mechanical barrier. In addition, occludin’s crucial role was in tight junction stability rather than tight junction assembly [25]. Therefore, although the morphological changes were accompanied by chronic inflammation, the
Effect of Psoralen

Fig. 5. Effect of psoralen on periodontal tissue of rats. Alveolar bone loss of maxillary second molar in rats (a). The changed expression of RANKL/OPG ratio in the periodontal tissue (b). Trabecular bone parameters BV/TV and Tb.Sp by micro-CT (c and d). Immunofluorescence staining of OPG and RANKL protein expression and micro-CT three-dimensional reconstruction (e). BV/TV, bone volume per tissue volume; Tb.Sp, trabecular separation. Bar graphs: Data are presented as mean ± SD. *P < 0.05. **P < 0.01. ***P < 0.001. Scale bars = 400 μm. Red means the positive expression of OPG and green means the positive expression of RANKL (e).

Fig. 6. The expression of inflammatory cytokines in serum. Concentration of the secretion of IL-6 from serum by ELISA (a). Concentration of the secretion of TNF-α from serum by ELISA (b). Concentration of the secretion of IL-10 from serum by ELISA (c). Bar graphs: Data are presented as mean ± SD. *P < 0.05. **P < 0.01.
expression level of occludin did not change, and the stability of tight junction was still maintained.

In the physiological state, the host recognises endogenous or exogenous microorganisms through intestinal NODs and maintains the gastrointestinal mucosal epithelial barrier by regulating the release of antimicrobial substances and maintaining the homeostasis of intestinal flora. NODs interact with symbiotic bacteria, and symbiotic bacteria promote the expression of NODs. Simultaneously, NOD negative feedback inhibits the proliferation of symbiotic bacteria. NODs play an important role in maintaining the balance between intestinal symbiotic flora and host immune response [26, 27]. NOD2 is an innate immune protein in gastrointestinal epithelial cells [28], which can recognise the teichoic acid dipeptide in the bacterial wall and mediate the activation of NF-κB (nuclear factor kappa-B) and the expression of the inflammatory cytokine TNF-α [27, 29], thus initiating the immune response to pathogens [30]. In this study, the expression of NOD2 in the intestinal mucosa of the Model group was found to be higher than that of the Control group, indicating that the intestinal immune barrier was activated. After intragastric administration of psoralen, the expression of NOD2 protein in the Peri+Pso group was significantly lower than that of Model. Psoralen alleviated intestinal injury and decreased the expression of NOD2 to some extent.

Recent studies have shown that bone metabolism such as bone growth and remodelling is closely related to intestinal microflora [31, 32]. Intestinal flora can maintain homeostasis of the host immune system, regulate the activity of osteoclasts and osteoblasts, and affect the balance of bone metabolism [33]. In this study, analysis of the alpha index of intestinal flora showed that the Chao1 index of the rats in the Pso group was significantly higher than that in the Control group, and the Shannon index in the rats in the Peri+Pso group was significantly higher than that in the Model group. The results showed that psoralen increased the abundance and diversity of intestinal flora in rats. Atarashi et al. [34] found that Clostridium can promote the number and function of Treg cells, form an environment rich in TGF-β (transforming growth factor-β), and inhibit the formation of osteoclasts. In addition, some studies have found that the Clostridium leptum subgroup can promote the production of Treg cells and secrete anti-inflammatory cytokines (such as IL-10) to inhibit self-traumatic inflammation. In this study, LEfSe analysis of intestinal flora in rats also found that the relative contents of o_Clostridiales and c_Clostridia in the Pso group increased, indicating that psoralen can increase the relative content of Clostridium in the intestines of healthy rats.

In addition, the F/B ratio was considered to be another significant indicator of microbial structure, as determined by the taxonomic composition [35]. In some studies on human osteoporosis, it was found that the F/B ratio in the osteoporosis group was higher than that in the Control group [36, 37]. However, we found that the decrease of the number of Firmicutes and the increase of the number of Bacteroidetes in the Pso and Peri+Pso groups led to the decrease in the F/B ratio and the decrease in ABL in the Peri+Pso group. It is suggested that psoralen can reduce the F/B ratio and ABL in periodontitis rats. At the same time, LEfSe analysis of intestinal flora showed that the relative content of p_Bacteroidetes in the Peri+Pso group increased. However, studies on senile osteoporotic rats and humans with low bone mineral density also found a decrease in the F/B ratio [38, 39]. This was similar to the increase in bone loss and the decrease in the F/B ratio in the Model group compared with the Control group in this study. Therefore, the role of the F/B ratio as a significant indicator of bone mineral density needs to be further elucidated.

The aforementioned results indicate that psoralen had a certain effect on the intestinal flora and immune barrier, to verify whether psoralen affected the intestinal tract and alveolar bone resorption. We further statistically analysed M2 ABL in rats and found significant ABL compared between the Control, Model, and Peri+Pso groups; however, ABL in the Peri+Pso group was significantly less than that in the Model group. Meanwhile, BV/TV of Model group was significantly lower than that of Control group and Peri+Pso group, while Tb.Sp was significantly higher than that of Control group and Peri+Pso group. It was suggested that psoralen can reduce alveolar bone resorption in periodontitis rats, and no significant difference was found in ABL between the Control and Pso groups. Combined with the results of NOD2 protein expression analysis in the ileal mucosal immune barrier in rats, psoralen had a significant effect during periodontitis; however, no significant change was observed under normal conditions. We speculate that psoralen mainly plays a role in inflammation and is related to the immune response.

Hereditity, hormones, immune system function, nutrition, and lifestyle factors play a decisive role in bone tissue mineralisation. Several mechanisms accelerate bone loss by altering the activity of osteoblasts and osteoclasts. For instance, bone mass loss mediated by oestrogen deficiency is associated with osteoclast differentiation and activity, in part due to the increased production of pro-inflammatory cytokines (TNF-α, IL-1, and IL-6) and the activation of immune cells [40]. At present, some scholars have
proposed that intestinal bacteria can lead to the activation of T cells in bone tissue. Inflammatory cytokines IL-6 and TNF-α secreted by T cells can promote gingival inflammation, accelerate periodontal connective tissue destruction, and alveolar bone resorption. TNF-α can induce the production of RANKL and macrophage colony stimulating factor (M-CSF) and downregulate OPG \[41, 42\]. TNF-α can also directly interact with osteoclast precursors and promote their differentiation and maturation. Through the receptor P55, TNF-α can enhance the response of bone marrow macrophages (BMM) to M-CSF and RANKL and indirectly promote BMM to differentiate into osteoclasts. However, IL-10 can inhibit T lymphocyte synthesis and production of IL-6, TNF-α, and interferons \[43–45\]. Therefore, we further detected the expression level of RANKL and OPG in periodontal tissues, and the levels of inflammatory cytokines IL-6, IL-10, and TNF-α in serum. This study found that the expression of OPG increased and the expression of RANKL decreased after administration of psoralen. The RANKL/OPG ratio in the Model group was higher than that in the Control group, and decreased after treatment with psoralen. At the same time, we found that there was no significant difference in IL-6 expression between the four groups; however, the content of TNF-α in the Peri+Pso group was significantly lower than that in the Model group. Additionally, the anti-inflammatory factor IL-10 in the Peri+Pso group was significantly higher than that in the Model group. Therefore, psoralen can promote the secretion of IL-10, inhibit the secretion of TNF-α, and slow down the inflammatory reaction. In conclusion, psoralen can potentially be used in the treatment of periodontitis. These results suggest that psoralen can potentially be used in the treatment of periodontitis.

**AUTHOR CONTRIBUTION**

Hua Liu and Yingjie Xu conceived and designed the study. Hua Liu, Yingjie Xu, Qi Cui, Ning Liu, Fuhang Chu, Beibei Cong, and Yingtao Wu performed the experiments. Hua Liu and Yingjie Xu wrote the paper. All authors read and approved the manuscript.

**FUNDING.**

This work was supported by the Shandong Province 2019-2020 TCM Technology Development Plan [No. 2019-0618] and the Qingdao Key Health Discipline Development Fund [No. 2020].

**DATA AVAILABILITY**

All data support our published claims and comply with field standards.

**CODE AVAILABILITY**

All software applications support our published claims and comply with field standards.

**DECLARATIONS**

**Ethics Approval.** All applicable international, national, and institutional guidelines for the care and use of animals were followed.

**Consent to Participate.** This manuscript does not contain any studies with human participants performed by any of the authors.

**Consent for Publication.** This manuscript does not contain any studies with human participants performed by any of the authors.

**Conflict of Interest.** The authors declare no competing interests.

**REFERENCES**

1. Slots, J. 2013. Periodontology: Past, present, perspectives. *Periodontology 2000* 62: 7–19. https://doi.org/10.1111/prd.12011.
2. Di Paola, R., S. Marzocco, E. Mazzon, F. Dattola, F. Rotondo, D. Britti, M. De Majo, T. Genovese, and S. Cuzzocrea. 2004. Effect of aminoguanidine in ligature-induced periodontitis in rats. *Journal of Dental Research* 83: 343–348. https://doi.org/10.1177/154405910408300414.
3. Palombo, E.A. 2011. Traditional medicinal plant extracts and natural products with activity against oral bacteria: Potential application in the prevention and treatment of oral diseases. *Evidence-based Complementary and Alternative Medicine* 2011. https://doi.org/10.1093/ecam/nep067.
4. Lamont, R.J., H. Koo, and G. Hajishengallis. 2018. The oral microbiota: Dynamic communities and host interactions. *Nature Reviews Microbiology* 16: 745–759. https://doi.org/10.1038/s41579-018-0089-x.
5. Kamer, A., R.G. Craig, A.P. Dasanayake, M. Brys, L. Glodzik-Sobanska, and M.J. de Leon. 2008. Inflammation and Alzheimer’s disease: Possible role of periodontal diseases. *Alzheimers Dement* 4: 242–250. https://doi.org/10.1016/j.jalz.2007.08.004.

6. Gao, L., T. Xu, G. Huang, S. Jiang, Y. Gu, and F. Chen. 2018. Oral microbiomes: More and more importance in oral cavity and whole body. *Protein & Cell* 9: 488–500. https://doi.org/10.1007/s13238-018-0548-1.

7. Xue, L., X. Zou, X.Q. Yang, F. Peng, D.K. Yu, and J.R. Du. 2020. Chronic periodontitis induces microbiota-gut-brain axis disorders and cognitive impairment in mice. *Experimental Neurology* 326: 113176. https://doi.org/10.1016/j.expneurol.2020.113176.

8. Holt, S.C., and J.L. Ebersole. 2005. Porphyromonas gingivalis, Treponema denticola, and Tannerella forsythia: The ‘red complex’, a prototype polybacterial pathogenic consortium in periodontitis. *Periodontology 2000* 38: 72–122. https://doi.org/10.1111/j.1600-0757.2005.00113.x.

9. Arimatuku, K., H. Yamada, H. Miyazawa, T. Minagawa, M. Nakajima, M.I. Ryder, K. Gotoh, D. Motooka, S. Nakamura, T. Iida, and K. Yamazaki. 2014. Oral pathobiont induces systemic inflammation and metabolic changes associated with alteration of gut microbiota. *Scientific Reports* 4: 4828. https://doi.org/10.1038/srep04828.

10. Nakajima, M., K. Arimatuku, T. Kato, Y. Matsuda, T. Minagawa, N. Takahashi, H. Ohno, and K. Yamazaki. 2015. Oral administration of P. gingivalis induces dysbiosis of gut microbiota and impaired barrier function leading to dissemination of enterobacteria to the liver. *PLoS One* 10: e0134234. https://doi.org/10.1371/journal.pone.0134234.

11. Sato, K., N. Takahashi, T. Kato, Y. Matsuda, M. Yokoji, Yamada Mikii, T. Nakajima, N. Kondo, N. Endo, R. Yamamoto, Y. Noiri, H. Ohno, and K. Yamazaki. 2017. Aggravation of collagen-induced arthritis by orally administered Porphyromonas gingivalis through modulation of the gut microbiota and gut immune system. *Scientific Reports* 7: 6955. https://doi.org/10.1038/s41598-017-0196-7.

12. Arron, J.R., and Y. Choi. 2000. Osteoimmunology-bone versus immune system. *Nature* 408: 535–536. https://doi.org/10.1038/35046196.

13. Britton, R.A., R. Irwin, D. Quach, L. Schaefer, J. Zhang, T. Lee, N. Rourke, B.A. Neilan, P. Vandamme, and L.R. McCabe. 2014. Probiotic L. reuteri treatment prevents bone loss in a menopausal ovariectomized mouse model. *Journal of Cellular Physiology* 229: 1822–1830. https://doi.org/10.1177/0022034518797275.

14. Chen, C.H., T.L. Hwang, L.C. Chen, T.H. Chang, C.S. Wei, and J.J. Chou. 2012. The osteoprotective effect of psoralen in periodontitis-induced alveolar bone loss in rats. *Journal of Cellular Physiology* 234: 1043–1044. https://doi.org/10.1002/jcp.27711.

15. Chopra, B., A.K. Dhingra, and K.L. Dhar. 2013. Psoralea corylifolia L. in rats. *Archives of Pharmacal Research* 33: 225–230. https://doi.org/10.1007/s12272-010-0206-5.

16. Wang, Y.X., X.Z. Chen, X.W. Chen, Z.H. Zhou, W.F. Xu, F. Xu, and S.Y. Zhang. 2019. AZD8835 inhibits osteoclastogenesis and periodontitis-induced alveolar bone loss in rats. *Journal of Cellular Physiology* 234: 1043–1044. https://doi.org/10.1002/jcp.27711.

17. Feng, L., L. Wang, and X.H. Jiang. 2010. Pharmacokinetics, tissue distribution and excretion of coumarin components from Psoralea corylifolia L. in rats. *Archives of Pharmacal Research* 33: 225–230. https://doi.org/10.1007/s12272-010-0206-5.
Atarashi, K., T. Tanoue, T. Shima, A. Imaoka, T. Kuwahara, Y. Momose, G. Cheng, S. Yamasaki, T. Saito, Y. Ohba, T. Taniguchi, K. Takeda, S. Horii, I.I. Ivanov, Y. Umesaki, K. Itoh, and K. Honda. 2011. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331: 337–341. https://doi.org/10.1126/science.1198469.

Everard, A., and P.D. Cani. 2013. Diabetes, obesity and gut microbiota. Best Practice & Research. Clinical Gastroenterology 27: 73–83. https://doi.org/10.1016/j.bpg.2013.03.007.

Wang, J., Y. Wang, W. Gao, B. Wang, H. Zhao, Y. Zeng, Y. Ji, and D. Hao. 2017. Diversity analysis of gut microbiota in osteoporosis and osteopenia patients. PeerJ 5: e3450. https://doi.org/10.7717/peerj.3450.

Das, M., O. Cronin, D.M. Keohane, E.M. Cormac, H. Nugent, M. Nugent, C. Molloy, P.W. O’Toole, F. Shanahan, M.G. Molloy, and I.B. Jeffery. 2019. Gut microbiota alterations associated with reduced bone mineral density in older adults. Rheumatology (Oxford) 58: 2295–2304. https://doi.org/10.1093/rheumatology/kez302.

Li, C., Q. Huang, R. Yang, Y. Dai, Y. Zeng, L. Tao, X. Li, J. Zeng, and Q. Wang. 2019. Gut microbiota composition and bone mineral loss-epidemiologic evidence from individuals in Wuhan, China. Osteoporosis International 30: 1003–1013. https://doi.org/10.1007/s10198-019-04855-5.

Ma, S., J. Qin, Y. Hao, and L. Fu. 2020. Association of gut microbiota composition and function with an aged rat model of senile osteoporosis using 16S rRNA and metagenomic sequencing analysis. Aging (Albany NY) 12: 10795–10808. https://doi.org/10.18632/aging.103293.

Pascale, A., N. Marchesi, C. Marelli, A. Coppola, L. Luzi, S. Govoni, A. Giustina, and C. Gazzaruso. 2018. Microbiota and metabolic diseases. Endocrine 61: 357–371. https://doi.org/10.1007/s12020-018-1605-5.

Jones, R.M., L. Luo, C.S. Ardita, A.N. Richardson, Y.M. Kwon, J.W. Mercante, A. Alam, C.L. Gates, H. Wu, P.A. Swanson, J.D. Lambeth, P.W. Denning, and A.S. Neish. 2013. Symbiotic lactobacilli stimulate gut epithelial proliferation via Nox-mediated generation of reactive oxygen species. The EMBO Journal 32: 3017–3028. https://doi.org/10.1038/emboj.2013.224.